NCT03229824

Brief Summary

Surgical site infection (SSI) after breast and axillary surgery occurs more often than for other clean surgical procedures. Infection in the setting of sick woman could delay the adjuvant therapy and result increase morbidity and mortality. Also this increased costs associated with health care.Surgical drains have been noted as a potential source for surgical site infections. The primary aim of the study is to determine if chlorhexidine occlusive dressings applied to the intervention drain sites effectively decreases rates of bacterial colonization in drain fluid and drain tips compared to standard care.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
116

participants targeted

Target at P50-P75 for not_applicable breast-cancer

Timeline
Completed

Started Oct 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 3, 2016

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

April 21, 2017

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 26, 2017

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 30, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2018

Completed
Last Updated

November 13, 2018

Status Verified

November 1, 2018

Enrollment Period

1.6 years

First QC Date

April 21, 2017

Last Update Submit

November 9, 2018

Conditions

Keywords

Drain antisepsisBacterial colonizationSurgical site infection

Outcome Measures

Primary Outcomes (2)

  • Number of subjects with drain bulb fluid bacterial colonization at the first and second week postoperative.

    Bacterial growth was defined as plate growth \>10\*5 colony forming unit (CFU). Drains were removed at variable times across patients, per clinical indication. When clinically indicated, some patients did have their drains removed at the one week visit, in which case they only had one bulb fluid culture.

    Approximately 1 or 2 weeks after surgery

  • Number of subjects with drain tip bacterial colonization at removal.

    Bacterial growth was defined as plate growth \>15 CFU by semiquantitative technique or \>10\*5 CFU by sonication and fluid culture. Drains were removed at variable times across patients, per clinical indication.

    Approximately at the second and/or third week after surgery

Secondary Outcomes (1)

  • Number of Subjects With Surgical Site Infection Within 30 Days

    Approximately 30 days after surgery

Study Arms (2)

Antiseptic occlusive dressing group

EXPERIMENTAL

A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.

Device: Antiseptic occlusive dressing group

Standard care

NO INTERVENTION

Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site and the tubing with a cotton swab dipped in rubbing alcohol.

Interventions

A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.

Also known as: Tegaderm CHG Dressing
Antiseptic occlusive dressing group

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Females minimum age 18 able to give informed consent
  • Breast cancer confirmed by histopathology
  • Patients undergoing unilateral or bilateral mastectomy with or without immediate expander reconstruction.

You may not qualify if:

  • Males
  • Patients who deny informed consent
  • Prior radiation therapy to the sick breast.
  • Pregnant or breastfeeding women
  • Patients undergoing immediate breast reconstruction with Deep Inferior
  • Epigastric Perforator (DIEP) o Transverse Rectus Abdominal Muscle techniques (TRAM) .
  • Emergency procedures
  • Documented allergy to chlorhexidine gluconate
  • Antibiotic use in the fourteen days prior to surgical date
  • Patients with a history or suspicion of breast cancer surgery outside the INCan in the previous three months.
  • Patients who do not speak spanish, diagnosed with a psychiatric disorder and in whom a minimum follow-up of 14 days couldn't be feasible because of operative difficulties (eg.
  • place of residence or reference to other health institutions).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Instituto Nacional de Cancerología

Mexico City, Mexico City, 14080, Mexico

Location

Related Publications (31)

  • Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar;65(2):87-108. doi: 10.3322/caac.21262. Epub 2015 Feb 4.

    PMID: 25651787BACKGROUND
  • Instituto Nacional de Geografía y estadística. "Estadísticas a propósito del día mundial de la lucha contra el cáncer de mama (19 de octubre)". Recuperado el 15 de febrero del 2016, de www.inegi.org.mx/aproposito/mama0

    BACKGROUND
  • Arce et al. Oncoguía: Cáncer de Mama. Cancerología 6, 2001; p77-86.

    BACKGROUND
  • Vilar-Compte D, Mohar A, Sandoval S, de la Rosa M, Gordillo P, Volkow P. Surgical site infections at the National Cancer Institute in Mexico: a case-control study. Am J Infect Control. 2000 Feb;28(1):14-20. doi: 10.1016/s0196-6553(00)90006-3.

    PMID: 10679132BACKGROUND
  • Olsen MA, Chu-Ongsakul S, Brandt KE, Dietz JR, Mayfield J, Fraser VJ. Hospital-associated costs due to surgical site infection after breast surgery. Arch Surg. 2008 Jan;143(1):53-60; discussion 61. doi: 10.1001/archsurg.2007.11.

    PMID: 18209153BACKGROUND
  • Olsen MA, Lefta M, Dietz JR, Brandt KE, Aft R, Matthews R, Mayfield J, Fraser VJ. Risk factors for surgical site infection after major breast operation. J Am Coll Surg. 2008 Sep;207(3):326-35. doi: 10.1016/j.jamcollsurg.2008.04.021. Epub 2008 Jun 26.

    PMID: 18722936BACKGROUND
  • Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, Morrell G, Dudeck MA, Pollock DA, Horan TC. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009 Dec;37(10):783-805. doi: 10.1016/j.ajic.2009.10.001. No abstract available.

    PMID: 20004811BACKGROUND
  • Felippe WA, Werneck GL, Santoro-Lopes G. Surgical site infection among women discharged with a drain in situ after breast cancer surgery. World J Surg. 2007 Dec;31(12):2293-9; discussion 2300-1. doi: 10.1007/s00268-007-9248-3.

    PMID: 17917771BACKGROUND
  • Ruvalcaba-Limon E, Robles-Vidal C, Poitevin-Chacon A, Chavez-Macgregor M, Gamboa-Vignolle C, Vilar-Compte D. Complications after breast cancer surgery in patients treated with concomitant preoperative chemoradiation: A case-control analysis. Breast Cancer Res Treat. 2006 Jan;95(2):147-52. doi: 10.1007/s10549-005-9058-y. Epub 2005 Dec 1.

    PMID: 16319989BACKGROUND
  • Prospero E, Cavicchi A, Bacelli S, Barbadoro P, Tantucci L, D'Errico MM. Surveillance for surgical site infection after hospital discharge: a surgical procedure-specific perspective. Infect Control Hosp Epidemiol. 2006 Dec;27(12):1313-7. doi: 10.1086/509838. Epub 2006 Nov 21.

    PMID: 17152028BACKGROUND
  • Vilar-Compte D, Jacquemin B, Robles-Vidal C, Volkow P. Surgical site infections in breast surgery: case-control study. World J Surg. 2004 Mar;28(3):242-6. doi: 10.1007/s00268-003-7193-3. Epub 2004 Feb 17.

    PMID: 14961196BACKGROUND
  • Vilar-Compte D, Rosales S, Hernandez-Mello N, Maafs E, Volkow P. Surveillance, control, and prevention of surgical site infections in breast cancer surgery: a 5-year experience. Am J Infect Control. 2009 Oct;37(8):674-9. doi: 10.1016/j.ajic.2009.02.010. Epub 2009 Jun 24.

    PMID: 19556033BACKGROUND
  • Vilar-Compte D, Roldan-Marin R, Robles-Vidal C, Volkow P. Surgical site infection (SSI) rates among patients who underwent mastectomy after the introduction of SSI prevention policies. Infect Control Hosp Epidemiol. 2006 Aug;27(8):829-34. doi: 10.1086/506395. Epub 2006 Jul 20.

    PMID: 16874643BACKGROUND
  • Landes G, Harris PG, Lemaine V, Perreault I, Sampalis JS, Brutus JP, Lessard L, Dionyssopoulos A, Nikolis A. Prevention of surgical site infection and appropriateness of antibiotic prescribing habits in plastic surgery. J Plast Reconstr Aesthet Surg. 2008 Nov;61(11):1347-56. doi: 10.1016/j.bjps.2008.02.008. Epub 2008 Jun 16.

    PMID: 18558522BACKGROUND
  • Throckmorton AD, Hoskin T, Boostrom SY, Boughey JC, Holifield AC, Stobbs MM, Baddour LM, Degnim AC. Complications associated with postoperative antibiotic prophylaxis after breast surgery. Am J Surg. 2009 Oct;198(4):553-6. doi: 10.1016/j.amjsurg.2009.06.003.

    PMID: 19800467BACKGROUND
  • Hedrick TL, Smith PW, Gazoni LM, Sawyer RG. The appropriate use of antibiotics in surgery: a review of surgical infections. Curr Probl Surg. 2007 Oct;44(10):635-75. doi: 10.1067/j.cpsurg.2007.06.006. No abstract available.

    PMID: 18021817BACKGROUND
  • XXXIII Congreso Nacional de la Asociación Mexicana de Infectología y Microbiología Clínica, A.C. León, Guanajuato; 14-17 de mayo de 2008.

    BACKGROUND
  • Throckmorton AD, Boughey JC, Boostrom SY, Holifield AC, Stobbs MM, Hoskin T, Baddour LM, Degnim AC. Postoperative prophylactic antibiotics and surgical site infection rates in breast surgery patients. Ann Surg Oncol. 2009 Sep;16(9):2464-9. doi: 10.1245/s10434-009-0542-1. Epub 2009 Jun 9.

    PMID: 19506959BACKGROUND
  • Penel N, Yazdanpanah Y, Chauvet MP, Clisant S, Giard S, Neu JC, Lefebvre D, Fournier C, Bonneterre J. Prevention of surgical site infection after breast cancer surgery by targeted prophylaxis antibiotic in patients at high risk of surgical site infection. J Surg Oncol. 2007 Aug 1;96(2):124-9. doi: 10.1002/jso.20796.

    PMID: 17443747BACKGROUND
  • Jones DJ, Bunn F, Bell-Syer SV. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. Cochrane Database Syst Rev. 2014 Mar 9;(3):CD005360. doi: 10.1002/14651858.CD005360.pub4.

    PMID: 24609957BACKGROUND
  • Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for Prevention of Surgical Site Infection, 1999. Centers for Disease Control and Prevention (CDC) Hospital Infection Control Practices Advisory Committee. Am J Infect Control. 1999 Apr;27(2):97-132; quiz 133-4; discussion 96.

    PMID: 10196487BACKGROUND
  • Purushotham AD, McLatchie E, Young D, George WD, Stallard S, Doughty J, Brown DC, Farish C, Walker A, Millar K, Murray G. Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer. Br J Surg. 2002 Mar;89(3):286-92. doi: 10.1046/j.0007-1323.2001.02031.x.

    PMID: 11872051BACKGROUND
  • Barbadoro P, Marmorale C, Recanatini C, Mazzarini G, Pellegrini I, D'Errico MM, Prospero E; Drainages Collaborative Working Group. May the drain be a way in for microbes in surgical infections? Am J Infect Control. 2016 Mar 1;44(3):283-8. doi: 10.1016/j.ajic.2015.10.012. Epub 2015 Dec 21.

    PMID: 26717874BACKGROUND
  • Simchen E, Rozin R, Wax Y. The Israeli Study of Surgical Infection of drains and the risk of wound infection in operations for hernia. Surg Gynecol Obstet. 1990 Apr;170(4):331-7.

    PMID: 2181714BACKGROUND
  • Degnim AC, Scow JS, Hoskin TL, Miller JP, Loprinzi M, Boughey JC, Jakub JW, Throckmorton A, Patel R, Baddour LM. Randomized controlled trial to reduce bacterial colonization of surgical drains after breast and axillary operations. Ann Surg. 2013 Aug;258(2):240-7. doi: 10.1097/SLA.0b013e31828c0b85.

    PMID: 23518704BACKGROUND
  • Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman LJ. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction. Ann Surg Oncol. 2014 Oct;21(10):3240-8. doi: 10.1245/s10434-014-3918-9. Epub 2014 Aug 6.

    PMID: 25096386BACKGROUND
  • Weichman KE, Clavin NW, Miller HC, McCarthy CM, Pusic AL, Mehrara BJ, Disa JJ. Does the use of biopatch devices at drain sites reduce perioperative infectious complications in patients undergoing immediate tissue expander breast reconstruction? Plast Reconstr Surg. 2015 Jan;135(1):9e-17e. doi: 10.1097/PRS.0000000000000810.

    PMID: 25539357BACKGROUND
  • Sankar B, Ray P, Rai J. Suction drain tip culture in orthopaedic surgery: a prospective study of 214 clean operations. Int Orthop. 2004 Oct;28(5):311-4. doi: 10.1007/s00264-004-0561-2. Epub 2004 Aug 14.

    PMID: 15316674BACKGROUND
  • Guembe M, Martin-Rabadan P, Cruces R, Perez Granda MJ, Bouza E. Sonicating multi-lumen sliced catheter tips after the roll-plate technique improves the detection of catheter colonization in adults. J Microbiol Methods. 2016 Mar;122:20-2. doi: 10.1016/j.mimet.2016.01.004. Epub 2016 Jan 14.

    PMID: 26778418BACKGROUND
  • Jost GF, Wasner M, Taub E, Walti L, Mariani L, Trampuz A. Sonication of catheter tips for improved detection of microorganisms on external ventricular drains and ventriculo-peritoneal shunts. J Clin Neurosci. 2014 Apr;21(4):578-82. doi: 10.1016/j.jocn.2013.05.025. Epub 2013 Aug 14.

    PMID: 24326253BACKGROUND
  • Anderson DJ, Podgorny K, Berrios-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist AC, Saiman L, Yokoe DS, Maragakis LL, Kaye KS. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Jun;35(6):605-27. doi: 10.1086/676022.

    PMID: 24799638BACKGROUND

MeSH Terms

Conditions

Breast NeoplasmsSurgical Wound Infection

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesWound InfectionInfectionsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Ethics Commissioner

Study Record Dates

First Submitted

April 21, 2017

First Posted

July 26, 2017

Study Start

October 3, 2016

Primary Completion

April 30, 2018

Study Completion

May 30, 2018

Last Updated

November 13, 2018

Record last verified: 2018-11

Locations